Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2011-09-20
- Lead Sponsor
- University of Florida
- Registration Number
- NCT00712062
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 80
- Registration Number
- NCT00703976
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 10
- Registration Number
- NCT00701857
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 598
- Registration Number
- NCT00686959
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 70
- Registration Number
- NCT00684099
- Locations
- 🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece
🇬🇷Sotiria" General Hospital, 1st Dep of Pulmonary Diseases, Athens, Greece
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 58
- Registration Number
- NCT00619424
- Locations
- 🇮🇹
GSK Investigational Site, Orbassano (TO), Piemonte, Italy
Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 124
- Registration Number
- NCT00614965
- Locations
- 🇬🇷
Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece
🇬🇷IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 1
- Registration Number
- NCT00612677
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2010-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 111
- Registration Number
- NCT00609518
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2011-12-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 106
- Registration Number
- NCT00606021
- Locations
- 🇸🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Riyadh, Saudi Arabia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.